The main advantages of anti-VEGF treatment over conventional laser photocoagulation include promoting rapid regression of acute-phase ROP, allowing potentials for retinal vascularization, approaching eyes with a rigid pupil, and a lower chance of unfavorable outcomes in type 1 ROP in zone I or posterior zone II (13). The gene discussed is VEGFA; the disease is retinopathy of prematurity.